A joint letter to the European Commission calls for a “market freeze” on new nicotine products, broad flavour bans, strict nicotine limits and national powers to ban nicotine pouches. It is a striking example of what happens when nicotine policy loses sight of relative risk.
Eight EU governments — the Netherlands, Belgium, Finland, France, Hungary, Latvia, Slovenia and Spain — have written to Health Commissioner Olivér Várhelyi demanding a much more restrictive approach to the forthcoming revision of the Tobacco Products Directive (TPD) and Tobacco Advertising Directive (TAD).
Some of their objectives are entirely reasonable. Nicotine products should be regulated. Minors should not use them. Manufacturers should meet proper product standards, marketing to children should not be tolerated and consumers should know what they are buying.
But the letter goes far beyond that. The governments call for what they explicitly describe as a “market freeze”, preventing new products containing nicotine or nicotine-like substances from entering the European market — even extending the principle to products containing no nicotine if they resemble nicotine products. They also demand strict nicotine limits, a broad flavour ban, standardised products and devices, plain packaging and regulation of different products “to the same extent” to prevent substitution between categories.
That last idea exposes the central problem. The letter repeatedly invokes “harm” while making almost no attempt to distinguish between radically different risk profiles. Reduced-risk claims are dismissed as unfounded, with no meaningful acknowledgement that the health risks of smoking are not remotely comparable to those of non-combustible nicotine products.
UK public-health guidance states that almost all the harm from smoking comes from toxic chemicals in smoke rather than nicotine. The UK Committee on Toxicity concludes that replacing cigarettes with appropriately manufactured nicotine pouches is likely to reduce overall health risk. And the US FDA has reached the same basic distinction after scientific review.
To ignore relative risk is not precautionary regulation. It is to ignore one of the most important facts in modern tobacco control.
Pouches are not cigarettes
Nicotine pouches are singled out for particularly hostile treatment. The ministers describe them as “highly harmful and addictive”, call them “strikingly similar” to snus and ask for Member States to be explicitly allowed to introduce national measures including a total ban on nicotine pouches.
The irony is difficult to miss. The EU’s snus ban may itself be one of the clearest examples of regulation undermining its own public-health objective: restricting access to a substantially lower-risk alternative for smokers. To invoke that ban as a precedent for restricting nicotine pouches risk repeating the same mistake on an even larger scale.
Nicotine pouches are addictive and not risk-free. But that does not make them remotely equivalent to cigarettes. A cigarette creates its extraordinary health burden through combustion and inhalation of smoke. A pouch does neither. Treating them as equivalent because both contain nicotine is rather like banning trains because cars are dangerous and both are forms of transport. The relevant question is what creates the risk.
In June, the FDA authorised 20 ZYN nicotine-pouch products to carry a modified-risk claim stating that using them instead of cigarettes lowers the risk of mouth cancer, lung cancer, heart disease, stroke, emphysema and chronic bronchitis. That authorisation applies to specific products, not an entire category, but it demonstrates that a major regulator can assess nicotine products according to relative risk rather than simply the presence of nicotine.
Smoking has not disappeared
This matters because smoking remains widespread in the countries signing the letter. Eurostat’s latest harmonised comparison puts current smoking at 11% in the Netherlands, 15% in Finland, 19% in Belgium, 24% in Spain and Slovenia, 26% in Hungary, 28% in France and 33% in Latvia, compared with 7% in Sweden and 24% across the EU.
Behind those percentages are millions of people. France has reported nearly 12 million daily smokers, Spain almost 7 million, and Hungary around 1.8 million adult smokers. Those three countries alone account for more than 20 million smokers on their respective national measures.
Against that background, making it easier to prohibit a non-combustible alternative while the product causing by far the greatest harm remains widely used is an extraordinary ordering of public-health priorities.
Youth protection is the strongest argument in the ministers’ letter, and it deserves to be taken seriously. But the comparable youth data do not support a simple gateway narrative. In the 2024 ESPAD survey of 15–16-year-olds, daily cigarette smoking was just 1.9% in Sweden, compared with 3.1% in France and rising to 19% in Hungary. Swedish national data similarly show only 2.3% of 16–29-year-olds smoking daily in 2024, despite nicotine-pouch use being concentrated in younger age groups.
There is nothing inconsistent about protecting minors while preserving lower-risk alternatives for adults. Enforce an 18+ age limit, robust age verification, restrictions on youth marketing, product standards, warnings and meaningful penalties for sales or proxy purchasing involving minors. Those measures target an identifiable problem. Blanket flavour bans, arbitrary nicotine limits and product bans are something else entirely.
“Future-proofing” by banning the future
The proposed market freeze is perhaps the strangest part of the letter. The governments call this “future-proof” regulation, yet the effect would be to prohibit future categories before anyone knows what they are, how they work or what risks they present.
That is not future-proofing. It is making the regulatory decision before the evidence exists.
Proper regulation should define the standards a new product must meet — toxicology, manufacturing quality, nicotine delivery, ingredients, labelling, marketing and protection of minors — and then assess products against those standards. The fact that something has not yet been invented is not a public-health risk assessment.
There is also a revealing shift in the objective of the letter. It begins by invoking the EU ambition of a “smoke-free generation by 2040”, but ends by calling for the “phasing out [of] nicotine dependence across the European Union.” Those are not the same goal.
If eliminating nicotine is the overriding objective, a smoker who switches completely to a nicotine pouch remains a policy failure. If reducing disease and death from smoking is the objective, the same switch can represent a major reduction in risk.
Europe should be clear about which problem it is trying to solve.
Sweden is the obvious counterpoint
Sweden provides the clearest European challenge to the approach set out in the letter. The latest harmonised Eurostat figure puts smoking at roughly one third of the EU average, while more recent national data are lower still: CAN — Sweden’s national competence centre for alcohol, drugs, doping, tobacco and gambling — found that just 3.7% of adults aged 18–84 smoked daily in 2025.
The health outcomes matter even more. EU data put tobacco-attributable mortality at 82 deaths per 100,000 in Sweden versus 118 across the EU. Among men, age-standardised lung-cancer incidence is 38.9 per 100,000 in Sweden compared with 94.5 across the EU. For anyone serious about reducing tobacco-related disease, this should be a scenario to understand and learn from, not an anomaly to regulate away.
Nor is Sweden’s record easily explained by uniquely punitive conventional tobacco control. What clearly distinguishes the country is the long-standing availability of non-combustible oral nicotine alternatives. The OECD’s 2025 Sweden health profile says the country’s success in reducing smoking is “largely attributed to the substitution of cigarettes with smokeless tobacco (snus).” Nicotine pouches are a separate, tobacco-free category, but the underlying harm-reduction mechanism is obvious: consumers have alternatives to combustion.
Swedish politics reflects that experience. The three largest parties in the newly elected Riksdag — the Social Democrats, Moderates and Sweden Democrats — together with the Christian Democrats, have all explicitly opposed an EU ban on nicotine pouches, commonly called “white snus” in Sweden. Together, those parties received 71.5% of the vote in the 2026 election. The remaining parliamentary parties — the Centre Party, Left Party and Greens — have instead argued that regulation of white snus should primarily remain a national competence. In other words, across the entire newly elected Riksdag there is no political constituency for Brussels simply banning the category.
But the deeper issue is not national sovereignty. It is how the Single Market is supposed to work.
The answer cannot be 27 governments inventing different nicotine limits, flavour rules and product bans on the basis of political preference. The TPD is an internal-market instrument based on Article 114 TFEU. Even the existing TPD provision allowing a Member State to prohibit a product category requires a specific national situation and a measure that is justified, necessary and proportionate to protecting public health; it is not a blank cheque for arbitrary restrictions.
There can be legitimate reasons for national departures from harmonised rules. But they should be supported by evidence showing that the restriction is actually likely to protect citizens. It is not enough to declare a product “harmful”, invent a threshold or ban a category and call the result public-health policy.
That is why Sweden matters. Before Europe suppresses alternatives to smoking — or gives governments broad latitude to do so — it needs a convincing evidence-based explanation for why the country with the continent’s lowest smoking prevalence and exceptionally favourable smoking-related outcomes has somehow got the model wrong.
Sensible regulation of nicotine pouches is both possible and desirable. What the Single Market should not become is a patchwork of arbitrary national restrictions built on the confusion of “not risk-free” with “significantly harmful.”
The next TPD should be built around evidence, proportionality, relative risk and genuine harmonisation. Otherwise Europe risks becoming highly effective at regulating nicotine while losing sight of the far more important objective: reducing the disease and death caused by smoking.
Sources
- Joint Letter on the revision of the TPD and TAD, 6 October 2026
https://berthub.eu/tkconv/document.html?nummer=2026D48852 - OECD – Country Health Profile 2025: Sweden
https://www.oecd.org/content/dam/oecd/en/publications/reports/2025/12/country-health-profile-2025-country-notes_7e72146d/sweden_89cbfa25/a77d5bfa-en.pdf - Eurostat – Sustainable Development in the European Union, 2026 edition
https://ec.europa.eu/eurostat/documents/15234730/23770550/KS-01-25-064-EN-N.pdf - CAN – Vanor och konsekvenser 2025
https://www.can.se/app/uploads/2026/03/can-rapport-242-vanor-och-konsekvenser-2025.pdf - Public Health Agency of Sweden – National Public Health Survey / Living habits, target area 6
https://www.folkhalsomyndigheten.se/pubreader/pdfview/121077?browserprint=1
